These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 21450673

  • 1. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B, Henriksson M, Lundin F, Wahlberg E.
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [Abstract] [Full Text] [Related]

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 3. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL.
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [Abstract] [Full Text] [Related]

  • 4. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C, Jacobsen J, Larsen AC, Schmidt EB, Johannesen NL, Videbaek J, Sørensen HT, Johnsen SP.
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [Abstract] [Full Text] [Related]

  • 5. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T.
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [Abstract] [Full Text] [Related]

  • 6. Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction.
    Feringa HH, Bax JJ, Karagiannis SE, Noordzij P, van Domburg R, Klein J, Poldermans D.
    Arch Gerontol Geriatr; 2009 Aug; 48(1):116-20. PubMed ID: 18177954
    [Abstract] [Full Text] [Related]

  • 7. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.
    Sigvant B, Kragsterman B, Falkenberg M, Hasvold P, Johansson S, Thuresson M, Nordanstig J.
    J Vasc Surg; 2016 Oct; 64(4):1009-1017.e3. PubMed ID: 27209402
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jönsson B, IDEAL Trial Investigators.
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Jun; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 Jun; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease.
    Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Wahlberg E.
    Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):39-46. PubMed ID: 19237996
    [Abstract] [Full Text] [Related]

  • 13. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P, Stenestrand U, Malmberg K, Jönsson B.
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group.
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J, Lindgren P, Spiesser J, Parry D, Jönsson B.
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [Abstract] [Full Text] [Related]

  • 16. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ, Prevention of Renal and Vascular End Stage Disease Study Group.
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [Abstract] [Full Text] [Related]

  • 17. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D, Park HJ, Ko SK.
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [Abstract] [Full Text] [Related]

  • 18. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD, Weiss JP, Owens DK.
    Am J Med; 2004 Jun 15; 116(12):797-806. PubMed ID: 15178495
    [Abstract] [Full Text] [Related]

  • 19. Role of statin therapy and angiotensin blockade in patients with asymptomatic moderate carotid artery stenosis.
    Durham CA, Ehlert BA, Agle SC, Mays AC, Parker FM, Bogey WM, Powell CS, Stoner MC.
    Ann Vasc Surg; 2012 Apr 15; 26(3):344-52. PubMed ID: 22285349
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
    Blinc A, Poredos P.
    Eur J Clin Invest; 2007 Mar 15; 37(3):157-64. PubMed ID: 17359482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.